At Moderna, our mission is to deliver the greatest possible impact to people through mRNA medicines—and we’re embarking on a journey to evaluate the use of mRNA science to treat cancer.
mRNA, short for messenger RNA, is a naturally occurring instructional molecule that tells your cells how to make proteins. For our investigational oncology products, scientists engineer mRNA molecules with instructions to make proteins that have the potential to stimulate the immune system to attack cancer cells.
Kyle Holen, MD
Head of Development, Therapeutics, and Oncology
With an investigational individual neoantigen therapy, each trial participant’s treatment is customized. To do this, researchers take and analyze a sample of the trial participant’s healthy genes and genes from their tumor. Based on this analysis, instructions are created and then loaded onto an mRNA molecule that has the potential to tell their body how to fight the cancer.
In immuno-oncology, also known as immunotherapy, the body’s own immune system may be used to potentially prevent or treat cancer.
Moderna is developing the use of mRNA in immuno-oncology by using the messenger molecule that we believe may activate the body’s immune system to attack tumor cells.
Discover new treatments. Advance medical research. Potentially gain access to investigational treatments.
At Moderna, we are dedicated to creating and developing innovative mRNA vaccines and therapies for a wide range of diseases that impact people’s lives, but we can’t do it alone. We invite you to partner with us on our journey to bring a new generation of transformative medicines to the world. Only people can help save people.
Thank you for your interest in participating as a Moderna-sponsored clinical research site.
Please complete all fields in this form for consideration. This information will be securely stored in Moderna’s clinical research site registry, which is managed by Citeline, and may be shared with Moderna’s CRO partners.
